在心房纤维化登记 (FLOW-AF): 患者特征,治疗模式和结果在埃及
Mohamed Sobhy1, Magdy Abdelhamid2, Adel Mohamed El Etriby3
1International Cardiac Center Hospital, 24 Bahaa Eldin Elghatwary St. Semouha, Alexandria, Egypt. sobhy53@yahoo.com.
Cardiology and therapy
|March 21, 2025
概括
埃及的FLOW-AF注册发现,新诊断的非膜心房动 (NVAF) 患者年轻,风险得分低于西方地区的患者. 治疗费用主要是由抗血栓药物驱动的.
科学领域:
- 心脏病学 心脏病学
- 流行病学 流行病学
- 药物经济学 药物经济学
背景情况:
- 在中东和北非 (MENA) 地区,特别是埃及,关于心房动 (AF) 的现实数据有限.
- 了解患者的特征和结果对于有效的管理至关重要.
研究的目的:
- 评估埃及新诊断的非膜动 (NVAF) 患者的特征,治疗模式和临床/经济结果.
- 为MENA地区的NVAF管理提供现实世界的见解.
主要方法:
- 在埃及进行的前性,观察性,多中心注册表 (FLOW-AF).
- 从2020年1月到2022年12月,招募了723名新诊断的NVAF患者.
- 在基线,6个月和12个月的随访期间收集的数据,包括人口统计数据,风险得分,治疗方法,临床事件和成本.
主要成果:
- NVAF患者的平均年龄为61.9岁,51.87%为女性.
- 平均CHA2DS2 -VASc和HAS-BLED分数分别为2.37和1.46. 这两个分数分别为2.37和1.46.
- 非维生素K对抗剂口服抗凝剂是最常见的治疗方法 (62.52%);抗血栓药物对成本贡献最大 (381.2美元/患者/年).
结论:
- 在该注册表中,埃及NVAF患者的年龄较小,风险得分较低,与西方和其他东方人口相比.
- 为了全面评估埃及的NVAF,需要对更大的队列和更长的随访进行进一步的研究.
相关概念视频
01:29Acute Respiratory Failure-V
768
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
768
01:25Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
377
Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
377
01:26Heart Failure III: Clinical Manifestations
1.2K
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.2K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
1.0K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.0K
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632